Two related proteins have been implicated in the mechanisms that allow breast cancer, and potentially other tumor types, to resist therapy with tyrosine kinase inhibitors (TKIs).
The facility is expected to have the same annual output as a conventional facility but in a single building.
New study finds that parallel microfiltration could lead to better treatments for a number of diseases.
Deal includes exclusive rights to use PS platform for commercial production of designated vaccine.
A team of investigators at Scripps report the discovery of a new type of chemical modification that affects numerous proteins within mammalian cells.
Both Catalent Pharma Solutions and UMN Pharma say they will expand their biologics development and manufacturing interests of multiple biosimilars in the Asian market through an alliance inked today. Japan based UMN Pharma and...
Grant intended to support manufacturing and development for rVSV-EBOV, including a new 330-person Phase Ib study
Agreement means firm can use platform for existing biodefense applications and all other vaccine indications.
Firms believe that they will help realise the vision for comprehensive, automated informatics solutions.